Close

pCDCAR1 BCMA h(BBζ) (CAR-ZP7715)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-BCMA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human BCMA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-BCMA antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Multiple Myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • BCMA
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Multiple Myeloma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-4-1BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigennonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 171
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • TNF receptor superfamily member 17
  • Synonyms
  • BCMA;TNFRSF17; TNF receptor superfamily member 17; BCM; BCMA; CD269; TNFRSF13A;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Retroviral transduction efficiency; cell surface staining of human T cells is consistent regardless of scFv.

CAR Construction : 171 scFv-28ζ Latest CAR Construction

Fig.1 Retroviral transduction efficiency; cell surface staining of human T cells is consistent regardless of scFv.

Results from representative single donor.

Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., ... & Brentjens, R. J. (2018). Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Molecular Therapy, 26(6), 1447-1456.

Complete CAR data FuncS

Fig.2 Superior Expansion of BCMA(171) and BCMA(125) scFv Containing CAR T Cells Demonstrated by Repeat Antigen Stimulation Assay.

CAR Construction : 171 scFv-28ζ Latest CAR Construction

Fig.2 Superior Expansion of BCMA(171) and BCMA(125) scFv Containing CAR T Cells Demonstrated by Repeat Antigen Stimulation Assay.

CAR T cells containing scFvs indicated (CD28 co-stimulatory domain) were placed on BCMA-aAPC or CD19-aAPC monolayers.

Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., ... & Brentjens, R. J. (2018). Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Molecular Therapy, 26(6), 1447-1456.

Complete CAR data Cyt

Fig.3 Cytotoxicity analysis; CAR+ T cells transduced with the same constructs as 1b are co-cultured at increasing E:T ratios with OPM2 human myeloma cell line.

CAR Construction : 171 scFv-28ζ Latest CAR Construction

Fig.3 Cytotoxicity analysis; CAR+ T cells transduced with the same constructs as 1b are co-cultured at increasing E:T ratios with OPM2 human myeloma cell line.

All scFvs lyse OPM2 cells in a dose-dependent manner. CAR T cells incorporating scFvs 183, 171, 130, and 125 are superior to 137; mean ± SEM.

Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., ... & Brentjens, R. J. (2018). Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Molecular Therapy, 26(6), 1447-1456.

Complete CAR data FuncS

Fig.4 Treatment with BCMA(171) CAR T cells provide significantly prolonged survival compared to treatment with CD19(SJ25C1) CAR T cells.

CAR Construction : 171 scFv-28ζ Latest CAR Construction

Fig.4 Treatment with BCMA(171) CAR T cells provide significantly prolonged survival compared to treatment with CD19(SJ25C1) CAR T cells.

Survival between mice treated with BCMA(171) CAR T cells differing by co-stimulatory domain were not significant.

Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., ... & Brentjens, R. J. (2018). Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Molecular Therapy, 26(6), 1447-1456.

Complete CAR data FCM

Fig.5 Generation and Validation of EGFRt/BCMA(171)-41BBz Containing CAR T Cell Therapy

CAR Construction : 171 scFv-28ζ Latest CAR Construction

Fig.5 Generation and Validation of EGFRt/BCMA(171)-41BBz Containing CAR T Cell Therapy

FACS shows both the EGFRt and the CAR are co-expressed on transduced donor T cells (quadrant V++).

Smith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., ... & Brentjens, R. J. (2018). Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Molecular Therapy, 26(6), 1447-1456.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-BCMA (171) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP7715). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.